Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, ventilator‑associated pneumonia, and severe sepsis in hospitalized patients.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections that require intravenous therapy.

Complicated intra‑abdominal infections: provides rapid bactericidal activity to resolve infection. Complicated urinary tract infections: eliminates resistant Gram‑negative and Gram‑positive pathogens. Hospital‑acquired pneumonia: achieves high lung tissue concentrations to treat resistant organisms. Ventilator‑associated pneumonia: offers coverage against multidrug‑resistant bacteria. Severe sepsis and septic shock: delivers systemic bacterial clearance in critically ill patients.

Adverse reactions may occur with any antimicrobial therapy. Monitoring for side effects is recommended during treatment.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea or vomiting: transient gastrointestinal discomfort. - Rash or pruritus: mild skin irritation. - Infusion site phlebitis: pain or redness at the injection site. - Headache: occasional mild headache. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea due to overgrowth. - Anaphylaxis: acute, life‑threatening allergic reaction. - Renal toxicity: worsening kidney function in susceptible individuals. - Thrombocytopenia: reduced platelet count leading to bleeding risk. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Careful assessment and monitoring are required before and during therapy. - Renal function: adjust dose in patients with impaired clearance. - Allergy: avoid if known hypersensitivity to carbapenems or β‑lactams. - Pregnancy: use only when benefits outweigh potential risks. - Valproic acid co‑administration: monitor for decreased seizure control. - Superinfection: watch for fungal or C. difficile overgrowth. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce plasma levels, increasing seizure risk. - Cytotoxic agents (e.g., cisplatin): additive nephrotoxicity. - Loop diuretics: heightened renal adverse effects.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined risk of nephrotoxicity. - Vancomycin: potential additive renal impairment. - Warfarin: may increase INR, requiring coagulation monitoring. - Oral contraceptives: possible reduction in hormonal efficacy, advise backup contraception.